Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01251861 · ClinicalTrials.gov registry record · Phase 2
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
A Phase 2 study of Recurrent Prostate Carcinoma and Stage III Prostate Cancer AJCC v7, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 20
- Study locations
NCT01251861 is a Phase 2 study of Recurrent Prostate Carcinoma and Stage III Prostate Cancer AJCC v7 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 108 participants, below the 162-participant average among 29 other Recurrent Prostate Carcinoma trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT01251861, a Phase 2 study of Recurrent Prostate Carcinoma and Stage III Prostate Cancer AJCC v7, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Clinical Observation
- DRUG Bicalutamide
- DRUG Akt Inhibitor MK2206
Study Locations (20)
Colorado
- The Medical Center of Aurora - Aurora
- Boulder Community Foothills Hospital - Boulder
- Penrose-Saint Francis Healthcare - Colorado Springs
- AdventHealth Porter - Denver
- Presbyterian - Saint Lukes Medical Center - Health One - Denver
- Saint Joseph Hospital - Cancer Centers of Colorado - Denver
- Rose Medical Center - Denver
- Western States Cancer Research NCORP - Denver
- Swedish Medical Center - Englewood
- Poudre Valley Hospital - Fort Collins
- Saint Mary's Hospital and Regional Medical Center - Grand Junction
- Banner North Colorado Medical Center - Greeley
- Saint Anthony Hospital - Lakewood
- AdventHealth Littleton - Littleton
- Sky Ridge Medical Center - Lone Tree
- Longmont United Hospital - Longmont
- Banner North Colorado Medical Center - Loveland Campus - Loveland
- AdventHealth Parker - Parker
California
- Stanford Cancer Institute Palo Alto - Palo Alto
- VA Palo Alto Health Care System - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2010-12-23 |
| Est. Completion | 2026-03-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01251861
The ClinicalTrials.gov registry entry for NCT01251861 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 29 other Recurrent Prostate Carcinoma trials with a reported enrollment target (33% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01251861 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Colorado, California.
Frequently Asked Questions
What is clinical trial NCT01251861 about?
NCT01251861 is a clinical study titled "Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer". This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens mad...
What is the current status of trial NCT01251861?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2010-12-23. Estimated completion is 2026-03-18.
What conditions does trial NCT01251861 study?
This clinical trial studies the following conditions: Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7.
What interventions are being tested in trial NCT01251861?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Clinical Observation (OTHER), Bicalutamide (DRUG), Akt Inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01251861?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01251861 being conducted?
This trial has 20 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers
RECRUITING · Phase 2
-
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
RECRUITING · Phase 2
-
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
ACTIVE NOT RECRUITING · Phase 2
-
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Recurrent Prostate Carcinoma
All registered trials for this condition
Stage III Prostate Cancer AJCC v7
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.